



TD Cowen 46th Annual Health Care Conference

March 2026



Forward Looking Statements

This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: our ability to effectively commercialize PALSONIFY (paltusotine) to become a market leader or new standard of care; our estimates relating to market size, or our ability to drive diagnosis and treatment for undiagnosed patients; the plans and timelines approval of paltusotine outside the US; the plans and timelines for a Phase 3 program, regulatory filings or approval of paltusotine for carcinoid syndrome, for atumelnant for CAH and for atumelnant for ACTH-dependent Cushing’s syndrome; the ability of atumelnant to transform CAH treatment or to become a “blockbuster” therapy for CAH; the ability of CRN09682 to become a “blockbuster” for neuroendocrine tumors or other SST2+ tumors; the plans and timelines for the clinical development of our drug candidates, including the therapeutic potential and clinical benefits or safety profile thereof; and the expected timing for the initiation of clinical trials or the potential benefits of our development candidates in patients across multiple indications; the expected timing of additional research pipeline updates or the expected timing of the advancement of those programs; and the expected timing through which our cash, cash equivalents, and short-term investments will fund our operating plans or its operating cash burn guidance. In some cases, you can identify forward-looking statements by terms such as “may,” “believe,” “anticipate,” “could,” “should,” “estimate,” “expect,” “intend,” “plan,” “project,” “will,” “contemplate,” “predict,” “continue,” “forecast,” “aspire,” “lead to,” “designed to,” “goal,” “aim,” “potential,” “target,” “vision” or other similar terms or the negatives thereof.

These statements speak only as of the date of this presentation, involve known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation: the data available at the time of data analysis; estimates relating to market size and growth potential, which involve a number of assumptions and limitations, particularly about any projections, assumptions, and estimates of our future performance; the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk; the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of our clinical trials and nonclinical studies; regulatory developments or political changes, policies related to pricing and pharmaceutical drug reimbursement in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization; our ability to obtain and maintain intellectual property protection for our product candidates; we may use our capital resources sooner than we expect or our cash burn rate may accelerate; and other risks described under the heading “Risk Factors” in documents we file from time to time with the Securities and Exchange Commission. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Our Mission:

To be **the world's leading endocrine company** that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives



Tony



Ellen



Wendy



Brittany



Dee



Lesley



Claire

Acromegaly

Carcinoid Syndrome

Congenital Adrenal Hyperplasia

ACTH-Dependent Cushing's Syndrome

NETs and SST2-Expressing Solid Tumors

Hyperparathyroidism

Graves' Disease

ADPKD

Obesity

Transforming Endocrine Disease Treatment from Discovery to Commercialization



In-House Discovery

- ✓ Proven **drug-hunters** in the difficult GPCR space
- ✓ Experienced team with a **robust pipeline** (9+ programs) of wholly owned assets with IP into the 2040s
- ✓ Additional value from **continued innovation**

Proven Development

- ✓ Demonstrated execution with **5 positive global Phase 2 or 3 readouts** in ~2 years and **first FDA approval** in 2025
- ✓ Steady stream of **upcoming clinical catalysts**


Commercial Execution

- ✓ Building global **commercial capabilities** supporting our endocrinology pipeline
- ✓ **Ensuring patients have access** to the next generation of treatments



Partnering with patients every step of the way.

2025: A Breakout Year



Building the Premier Endocrinology Business

PALSONIFY: Strong Commercial Fundamentals Reflect Early Success

Patients

Activated and
Motivated

>200

Enrollment Forms

22/22

Enrollment Forms from
U.S. OLE Patients

Providers

Adopting with
Confidence

>125

Unique Palsonify
Prescribers

~50% | ~50%

Prescriber Setting
Community | PTC

Payers

Recognizing Value
Proposition

~50% / ~50%

Reimbursed vs. Quickstart
for Newly Filled Bottles

12 Months

Duration of Most
Prior Authorizations

\$5.4M PALSONIFY 4Q2025 Net Product Revenue

Note: Data as of December 31, 2025. An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify. Pituitary treatment centers (PTCs) or community practices may also choose to submit an enrollment form to CrinetiCARE when dispensing the medication directly to the patient. 81% of prior authorizations have a minimum 300-day duration based on data from specialty pharmacies. Abbreviations: OLE, Open-Label Extension; PTC, Pituitary Treatment Center.

Upcoming Milestones

★ Potential 2026 Milestone

Paltusotine

- ★ Commercial execution of PALSONIFY in the U.S.
- ★ Advancing paltusotine in other geographies
- Phase 3 CAREFNDR readout in carcinoid syndrome

Atumelnant

- ★ Phase 2/3 Equilibrium trial initiation in ADCS
- ★ Additional data from ongoing Phase 1b/2a study in ADCS
- ★ Longer duration of data from OLE portion of TouCAHn in adult CAH
- Phase 2 interim data from BALANCE in pediatric CAH
- Phase 3 CALM readout in adult CAH
- Phase 3 BALANCE readout in pediatric CAH

CRN09682

- ★ Phase 1/2 BraveSST2 dose escalation/expansion in NETs, potential interim data

Early-Stage

- ★ Continued innovation from Discovery team on key endocrinology targets



Thank You

